Product logins

Find logins to all Clarivate products below.


Hemophilia A – Landscape & Forecast – Disease Landscape & Forecast

The acceptance of Roche / Chugai’s nonfactor bispecific antibody Hemlibra as a key treatment for hemophilia A has changed the treatment landscape. Hemlibra has been transformative for many inhibitor patients who were on bypass agent prophylaxis, providing improved treatment outcomes. It is also a more-convenient prophylaxis option for noninhibitor patients due to its lower dosing frequency and SC administration. The next 10 years will be exciting for the hemophilia A (with and without inhibitors) therapy market owing to the entry of an extended half-life factor VIII product (Sanofi / Sobi’s Altuviiio / Altuvoct), several nonfactor agents (Sanofi’s fitusiran, Pfizer’s marstacimab, and Novo Nordisk’s concizumab and Mim8), and gene therapies (BioMarin’s Roctavian, Pfizer / Sangamo Therapeutics’ giroctocogene fitelparvovec). Supported by insights from thought leaders, we assess the impact of new drugs on the treatment of hemophilia A.

Questions answered

  • What is the current treatment landscape for hemophilia A? What are physicians’ experience and satisfaction levels with key therapies?
  • How has Hemlibra changed the treatment landscape for hemophilia A for patients with and without inhibitors?
  • What clinical roles will Altuviiio, concizumab, fitusiran, marstacimab, Mim8, and gene therapy play in the evolving hemophilia A treatment landscape?
  • How will the management of patients with and without inhibitors change when new treatment options become available?
  • How will the factor VIII concentrate market evolve?
  • How will nonfactor treatment options impact the multitude of brands competing for patient share?

Geography: United States, EU5, Japan

Primary research: 19 country-specific interviews with thought-leading hematologists and supported by survey data collected for this and other Clarivate research

Epidemiology: Diagnosed prevalence of hemophilia A +/-inhibitors by country, population segmentation by disease severity and inhibitor titer

Forecast: 10-year, annualized, drug-level sales and patient share of key hemophilia A therapies through 2033, segmented by brands and epidemiological subpopulations

Drug treatments: Coverage of select current and emerging therapies

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents


Related Market Assessment Reports

Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 722 currently available and novel biosimilar products, detailing…
Report
Psoriasis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The psoriasis therapy market has become increasingly lucrative due to the growing use of targeted agents. The newer IL-17 and IL-23 inhibitors (e.g., Eli Lilly’s Taltz, Johnson & Johnson…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…